GLP-1RAs can have a number of side effects, including gastrointestinal side-effects, loss of muscle mass, headache and fatigue
GLP-1RA corrects this imbalance through the following mechanisms: cell function protection and regeneration: GLP-1RA not only promotes insulin synthesis through cAMP-PKA pathway, but also realizes the increase of cell number and functional recovery by inhibiting cell apoptosis and promoting cell to cell transdifferentiation (for example, GCGR monoclonal antibody combined with GLP-1RA treatment can triple the number of cells in type 1 diabetes mice)
One may experience physical sensations such as tingling, warmth, coolness, a feeling of lightening or leaving the body, or a momentary twitch as energy moves through the body
This ovoprotective effect is suggested to be mediated through activation of different SIRT1-mediated protective signaling pathways that remodel ovarian redox status, inflammation, and apoptosis, which may strengthen the potential role of SP and L-car as a chemotherapy adjuvant, reducing the negative health effects of early menopause after cancer therapy
A phase III clinical trial was completed to see if metformin could be a good treatment option for patients with HS, but results are not yet publicly available
How about addressing weight balance by supplementing with nutrients that encourage the natural production of GLP1 from the enteroendocrine cells of the human small intestinal lining that act to provide an adequate level of GLP1
